Matthew K Fust insider trades: Crinetics Pharmaceuticals (CRNX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matthew reports to the SEC
and 2 more companies
Open-market buys and sales
41 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | CRNX | ↓ Sell | 16,000 | $44.75 | $716K | Direct | Sep 30, 2025 (4d) |
| Oct 18, 2024 | NMRA | ↓ Sell | 21,788 | $17.03 | $371K | Direct | Oct 18, 2024 (0d) |
| Mar 20, 2024 | CRNX | ↓ Sell | 47,500 | $44.28 | $2.1M | Direct | Mar 22, 2024 (2d) |
| Mar 7, 2024 | RARE | ↓ Sell | 12,195 | $50.88 | $620K | Direct | Mar 11, 2024 (4d) |
| Jul 13, 2022 | CRNX | ↓ Sell | 5,700 | $20.96 | $119K | Direct | Jul 15, 2022 (2d) |
| Nov 4, 2021 | ATRA | ↓ Sell | 13,354 | $19.50 | $260K | Direct | Nov 5, 2021 (1d) |
| Nov 1, 2021 | CRNX | ↓ Sell | 8,954 | $25.50 | $228K | Direct | Nov 3, 2021 (2d) |
| Sep 8, 2021 | CRNX | ↓ Sell | 6,046 | $25.50 | $154K | Direct | Sep 9, 2021 (1d) |
| Jul 26, 2021 | CRNX | ↓ Sell | 5,000 | $19.59 | $98K | Direct | Jul 27, 2021 (1d) |
| Jul 19, 2021 | CRNX | ↓ Sell | 5,000 | $19.50 | $98K | Direct | Jul 20, 2021 (1d) |
| Jul 12, 2021 | CRNX | ↓ Sell | 5,000 | $20.71 | $104K | Direct | Jul 13, 2021 (1d) |
| Jul 6, 2020 | RARE | ↓ Sell | 6,181 | $90.00 | $556K | Direct | Jul 8, 2020 (2d) |
| Jul 1, 2020 | RARE | ↓ Sell | 5,000 | $85.00 | $425K | Direct | Jul 6, 2020 (5d) |
| May 18, 2020 | RARE | ↓ Sell | 1,875 | $75.00 | $141K | Direct | May 19, 2020 (1d) |
| Apr 22, 2020 | RARE | ↓ Sell | 1,875 | $65.00 | $122K | Direct | Apr 24, 2020 (2d) |
| Dec 24, 2019 | DERM | ↓ Sell | 3,000 | $15.00 | $45K | Direct | Dec 26, 2019 (2d) |
| Dec 16, 2019 | CRNX | ↓ Sell | 3,500 | $22.50 | $79K | Direct | Dec 18, 2019 (2d) |
| Dec 12, 2019 | DERM | ↓ Sell | 3,000 | $12.00 | $36K | Direct | Dec 13, 2019 (1d) |
| Sep 12, 2019 | DERM | ↓ Sell | 6,000 | $8.77 | $53K | Direct | Sep 16, 2019 (4d) |
| Feb 6, 2019 | MGNX | ↓ Sell | 6,924 | $29.38 | $203K | Direct | Feb 8, 2019 (2d) |
| Oct 19, 2018 | DERM | ↓ Sell | 4,000 | $13.75 | $55K | Direct | Oct 19, 2018 (0d) |
| May 30, 2018 | RARE | ↓ Sell | 6,319 | $72.00 | $455K | Direct | May 30, 2018 (0d) |
| May 14, 2018 | ATRA | ↓ Sell | 12,286 | $43.57 | $535K | Direct | May 16, 2018 (2d) |
| Nov 25, 2014 | DERM | ↑ Buy | 6,000 | $16.77 | $101K | Direct | Nov 26, 2014 (1d) |
| Jan 30, 2014 | RARE | ↑ Buy | 5,000 | $21.00 | $105K | Direct | Feb 3, 2014 (4d) |
| Aug 8, 2013 | ONXX | ↓ Sell10b5-1 | 2,492 | $128.21 | $319K | Direct | Aug 12, 2013 (4d) |
| Jul 26, 2013 | ONXX | ↓ Sell10b5-1 | 6,043 | $130.50 | $789K | Direct | Jul 29, 2013 (3d) |
| Jul 2, 2013 | ONXX | ↓ Sell10b5-1 | 1,551 | $132.80 | $206K | Direct | Jul 5, 2013 (3d) |
| May 13, 2013 | ONXX | ↓ Sell10b5-1 | 10,269 | $98.22 | $1.0M | Direct | May 15, 2013 (2d) |
| Apr 15, 2013 | ONXX | ↓ Sell10b5-1 | 1,347 | $95.15 | $128K | Direct | Apr 16, 2013 (1d) |
| Apr 1, 2013 | ONXX | ↓ Sell10b5-1 | 3,861 | $86.14 | $333K | Direct | Apr 3, 2013 (2d) |
| Feb 28, 2013 | ONXX | ↓ Sell10b5-1 | 15,000 | $77.12 | $1.2M | Direct | Mar 4, 2013 (4d) |
| Jan 10, 2013 | ONXX | ↓ Sell10b5-1 | 10,199 | $84.87 | $866K | Direct | Jan 11, 2013 (1d) |
| Aug 6, 2012 | ONXX | ↓ Sell | 22,009 | $71.71 | $1.6M | Direct | Aug 8, 2012 (2d) |
| Jul 25, 2012 | ONXX | ↓ Sell | 5,207 | $73.97 | $385K | Direct | Jul 27, 2012 (2d) |
| Mar 2, 2012 | ONXX | ↓ Sell10b5-1 | 592 | $37.52 | $22K | Direct | Mar 6, 2012 (4d) |
| Jan 6, 2012 | ONXX | ↓ Sell10b5-1 | 1,789 | $43.46 | $78K | Direct | Jan 10, 2012 (4d) |
| Nov 18, 2011 | ONXX | ↓ Sell10b5-1 | 867 | $38.05 | $33K | Direct | Nov 21, 2011 (3d) |
| Apr 1, 2011 | ONXX | ↓ Sell10b5-1 | 800 | $35.02 | $28K | Direct | Apr 4, 2011 (3d) |
| Jan 6, 2011 | ONXX | ↓ Sell10b5-1 | 1,812 | $37.28 | $68K | Direct | Jan 7, 2011 (1d) |
| Jan 6, 2010 | ONXX | ↓ Sell10b5-1 | 1,919 | $29.60 | $57K | Direct | Jan 7, 2010 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CRNX insiders
Open-market trades in the last 12 months
About Matthew K Fust's insider trades
Matthew K Fust is a director at Crinetics Pharmaceuticals (CRNX). Since Jan 6, 2010, Matthew has reported 2 open-market purchases worth $206K and 39 sales worth $14.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
14 sales (35% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (59 filings), option exercises (38 filings), shares returned to the company (8 filings), other transactions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRNX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.